Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Schultz

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Journal of Molecular Neuroscience : MN|June 13, 2002
A phase I study of AIT-082 in healthy elderly volunteersMichael Grundman, Martin Farlow, Guerry Peavy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern eraA M Varghese, A Arora, M Capanu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)J Mateo, D Chakravarty, R Dienstmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
Archives of Neurology|January 21, 2004
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman, Ronald C Petersen, Steven H Ferris, et al.
Head & Neck|August 3, 2004
Parathyroid carcinoma: a 22-year experienceNaifa L Busaidy, Camilo Jimenez, Mouhammed Amir Habra, et al.
Mutation Research|June 12, 1996
The detection and evaluation of aneugenic chemicalsJ M Parry, E M Parry, R Bourner, et al.
High Altitude Medicine & Biology|March 21, 2006
Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trialBuddha Basnyat, Jeffrey H Gertsch, Peter S Holck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancerK Hastings, H A Yu, W Wei, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Journal of Molecular Neuroscience : MN|June 13, 2002
A phase I study of AIT-082 in healthy elderly volunteersMichael Grundman, Martin Farlow, Guerry Peavy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern eraA M Varghese, A Arora, M Capanu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)J Mateo, D Chakravarty, R Dienstmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
Archives of Neurology|January 21, 2004
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman, Ronald C Petersen, Steven H Ferris, et al.
Head & Neck|August 3, 2004
Parathyroid carcinoma: a 22-year experienceNaifa L Busaidy, Camilo Jimenez, Mouhammed Amir Habra, et al.
Mutation Research|June 12, 1996
The detection and evaluation of aneugenic chemicalsJ M Parry, E M Parry, R Bourner, et al.
High Altitude Medicine & Biology|March 21, 2006
Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trialBuddha Basnyat, Jeffrey H Gertsch, Peter S Holck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancerK Hastings, H A Yu, W Wei, et al.
Pageof 10